TX-MYTHICAL-GAMES
30.5.2024 19:30:28 CEST | Business Wire | Press release
Pudgy Penguins, the brand development company behind the series of globally recognized Pudgy Penguins characters, and next-generation gaming technology studio Mythical Games today announced a partnership to create a unique web3-enabled mobile video game. The partnership unites the creators of the globally recognized Pudgy Penguins characters and the gaming studio behind two of the most successful blockchain games ever, NFL Rivals and Blankos Block Party.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530595937/en/
Details of the forthcoming game developed in conjunction with Mythical Games were announced at Consensus 2024. The upcoming mobile game will be an immersive video game drawing upon the lore and humor that have made Pudgy Penguins so beloved, coupled with AAA quality, playability, and accessibility synonymous with Mythical Games' title NFL Rivals. The new game is scheduled to launch on the Mythical platform in 2025, home to NFL Rivals, with over 5 million players, and the Mythos Chain (MYTH), with over one million active wallets.
“Web3 in gaming is evolving quickly, but one thing that hasn’t changed is the need for games to be powered by strong communities and great gameplay,” said John Linden, Mythical Games CEO. “Pudgy Penguins is the only web3 project to truly go mainstream through their incredible retail partnerships with Walmart and Target and their rapidly growing social media following. We are excited to combine their efforts with a game that will be played by millions. Building this with Mythical Games on the Mythical Platform and Mythos Chain, already used by millions of consumers, is going to be a major driver to further push web3 with mainstream consumers.”
Luca Netz, CEO of Pudgy Penguins said: “When we decided to create a mobile-first AAA blockchain-based Pudgy Penguins game, working with Mythical Games is something that excited me. Our growth strategy that has reached millions, combined with Mythical Games’ experience and success with gaming, sets up this endeavor for success. We can’t wait to show the Pudgy Penguins community what’s in store and solicit their feedback as development ramps up.”
In the build-up to its release, Pudgy Penguins holders will be treated to exclusive content, sneak peeks of in-game footage and given the opportunity to help shape key aspects of the game’s development. The game is designed to appeal to the Pudgy Penguins community as well as the broader gaming market to further grow the Pudgy Penguins’ brand and ethos.
Ahead of the game's launch in 2025, interested players can join Pudgy Penguins Discord, and follow Pudgy Penguins (@pudgypenguins) and Mythical Games (@playmythical) Twitter/X accounts to stay updated on the upcoming game.
About Pudgy Penguins
Pudgy Penguins is dedicated to making Web3 accessible to everyone by creating innovative products that enable seamless onboarding. Their focus on community empowerment and building brand awareness has made them a leader in the Web3 space while also disrupting the traditional web2, retail sphere. They're committed to impacting the everyday consumer and shaping the future of Web3.
Learn more: https://www.pudgypenguins.com/
About Mythical Games
Acknowledged by Fast Company’s World Changing Ideas 2021 and recently Forbes’ Best Startup Employers (2024), Mythical Games is a next-generation game company creating world-class games and empowering players to take ownership of their in-game assets through the use of blockchain technology. The team has helped develop major franchises, including Call of Duty, Call of Duty Mobile, World of Warcraft, Diablo, Overwatch, Magic: The Gathering, EA Madden, Harry Potter Hogwarts Mystery, Marvel Strike Force, Modern Warfare 3, and Skylanders.
The Mythical Marketplace, the first in-game blockchain Marketplace on iOS and Android, provides gamers with ownership and control over the purchase and sale of digital assets, while the Mythical Platform protects gamers that may be new to blockchain through a custodial wallet for their digital items.
Mythical Games is one of the 22 founding member companies of the Mythos Foundation (http://mythos.foundation) utilizing the Mythos Chain as its blockchain and Mythos’ MYTH token as the utility token for the Mythical Marketplace.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530595937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom